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1. Abstract 
 
Background and aims: The detection and removal of precancerous lesions 
through colorectal cancer (CRC) screening, and the intervention on modifiable 
risk factors for CRC - such as smoking habits, physical activity, red meat 
consumption and alcohol intake - represent the two possible ways for reducing 
CRC incidence and mortality. The aim of this project was to investigate 
whether lifestyle factors, gender, family history and daily low-dose Aspirin 
use are important factors in predicting endoscopy findings at a first round 
screening level and whether they can have a significant impact on the natural 
history of the disease in screened patients during their follow-up (second 
round screening level). 
 
Patients and methods: Me and my work team identified and selected a study 
population of 870 men and women of age 50-74 years who underwent a 
screening colonoscopy at the European Institute of Oncology (IEO) between 
the years 2007-2009 after a positive Fecal Occult Blood Test (FOBT+). We 
set up a telephone questionnaire in order to retrieve information on smoking 
habits, BMI, physical activity, diet, alcohol consumption, family history and 
usage of low-dose Aspirin at the time of the first colonoscopy. All patients 
were then interviewed by me by telephone. Ninety-five individuals were not 
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interviewed for various reasons, making the final population size n=775. 
Patients who could answer the questionnaire were similar to the unreached 
individuals in terms of outcome of the first colonoscopy. 
 
Results: At first colonoscopy, we observed 415 patients presenting with a 
high-risk neoplasia (i.e. 3 or more adenomas or at least one adenoma bigger 
than 10 mm / with villous component / with high-grade dysplasia or invasive 
tumor). At the univariate analysis, gender, family history, physical activity, 
smoking habits, alcohol intake, fruit and vegetable intake and daily low-dose 
Aspirin were associated with the prevalence of high-risk neoplasia. Using a 
“Spike at zero function”, we showed that light drinkers (<5 grams per day) 
seemed to have a lower risk of high-risk neoplasia compared to non-drinkers. 
We concluded that a proportion of non-drinkers might avoid alcohol because 
of some health conditions linked to the endpoint of interest. At a multivariable 
level, all those factors remained statistically significantly associated with the 
outcome of interest. We therefore combined the information of lifestyle 
factors, gender, family history and daily low-dose Aspirin use to obtain a 
reliable individual risk score (i.e. linear predictor) and build a nomogram.  
The second colonoscopy visit date was fixed in advanced at the time of first 
colonoscopy, based on the outcome of the first colonoscopy, following a 
typical example of Doctor’s care scheme of examinations. After adjusting for 
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the severity of the outcome of the first colonoscopy and for the time from first 
to second colonoscopy, we obtained a statistically significant association 
between the linear predictor and the risk of high-risk neoplasia detected at the 
second colonoscopy. 
We then applied homogeneous Markov Models to simultaneously model the 
disease process over time. The effect of the linear predictor on the transitions 
– from one disease stage to the other – resulted statistically significant. 
Moreover, as the linear predictor increased, the probability of getting better 
decreased. In other words, the worse the lifestyle, the lower the probability for 
the intestinal mucosa to heal. On the other hand, the estimated parameter for 
the effect of linear predictor on the aggravation transition resulted positive: 
the worse the lifestyle, the higher the probability to find new high-risk polyps.  
 
Conclusions: Lifestyle should be considered in the planning of population 
CRC screenings, because the identification of different risk groups can lead to 
more tailored screening policies, and accordingly to more efficient and cost-
effective interventions. 
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2. The project 
 
2.1 Background and aims 
 
Colorectal cancer (CRC) is the third most commonly diagnosed cancer 
in males and the second in females, with over 1.2 million new cancer cases 
and 608,700 deaths estimated to have occurred in 2008 worldwide1. The 
detection and removal of precancerous lesions through CRC screening, and 
the intervention on modifiable risk factors for CRC, such as smoking, physical 
activity, red and processed meat consumption, and alcohol intake, represent 
the two possible ways for reducing CRC incidence and mortality. Regarding 
the modifiable factors associated with CRC risk, through the past 2 decades, 
while a consistent association between cigarette smoking and colorectal 
adenomatous polyps, recognized precursor lesions of CRC2,3 (Figure 2.1), has 
been shown, the smoking-CRC link remained controversial until the very 
recent years. 
 
Figure 2.1 The adenoma-carcinoma sequence, from normal epithelium to 
tumor infiltration of the basement membrane 
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 Our group provided strong evidence on the detrimental effect of 
cigarette smoking on the development of both colorectal adenomatous polyps 
and CRC, based on two systematic reviews of the literature and meta-
analyses4,5. In the first study on adenomas, we also showed that the smoking-
related increase of risk was significantly greater for high-risk adenomas 
(villous component or size >10 mm or severe dysplasia) compared to low-risk 
adenomas, suggesting that smoking may be important for both the formation 
and aggressiveness of adenomas4. In the second study on cancer, we showed 
how cigarette smoking is significantly associated with both CRC incidence 
and mortality5.  
 
Besides smoking, strong evidence on the association between gender, 
body mass index (BMI), family history, physical activity and the incidence of 
CRC is well reported in the literature7-10. Moreover, there is emerging 
indication that alcohol consumption, diet, and daily low-dose Aspirin are 
possible additional factors associated with the risk of CRC11-13.  
 
Since all these associations could have important implications on future 
screening policies6,14, I here present a project aiming at showing that lifestyle-
related factors - smoking, alcohol consumption, diet, physical activity and 
BMI - together with gender, family history and daily low-dose Aspirin use, 
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could be important factors in predicting endoscopy findings at a first round 
screening level and that the same factors may also impact on the natural 
history of the disease in screened patients. In other words, our goal is to show 
that lifestyle, together with gender, family history and daily low-dose Aspirin 
use, could possibly represent an important factor to consider when a) deciding 
on the age at which CRC screening should begin, either by lowering the age in 
individuals with a poor lifestyle or increasing the age in individuals with a 
healthy lifestyle and b) deciding how much time should pass from the first 
screening colonoscopy to the second control colonoscopy, basing the future 
indications on the finding of the primary colonoscopy as well as on the 
patients’ characteristics. 
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2.2 Patients  
 
Since 2005, the Italian National Health System has implemented a 
screening program for CRC for all citizens of 50 years of age or more. 
Screening tests are free for the target population (so-called Minimal Care 
Level guaranteed for all Italian citizens). Invitees are asked to take an 
immunological test for Fecal Occult Blood (FOBT) every two years. 
Individuals with a positive FOBT test are invited to undergo a total 
colonoscopy in an SSN-accredited Endoscopy Department. 
 
The identification of the present study population was performed using 
the Database of the Division of Endoscopy of the European Institute of 
Oncology (IEO), which collects data on all the IEO patients receiving any 
health service for the diseases of the gastrointestinal tract and data on their 
endoscopic findings. We identified and selected a study population of 870 
men and women of age 50-74 years who underwent a screening colonoscopy 
at the IEO between the years 2007-2009 after a positive FOBT. All the 
patients were participants to the Colorectal Cancer Screening Program of the 
Lombardy Region.  
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We decided to select a high-risk population (FOBT positive) in order to 
work with a larger number of events and consequently gain an adequate power 
for the study.  
 
Since the relation lifestyle-colorectal neoplasia could be biased by 
different behavioral correlates of lifestyle, such as tendency for people who a 
poor lifestyle to delay seeking medical care, we decided to include only 
asymptomatic patients presenting for their first screening colonoscopy. 
Patients who had undergone a colonoscopy before the first screening 
colonoscopy were excluded. Furthermore, patients with any previous or 
present disease that could affect the lifestyle-related adenoma risk, such as 
hereditary CRC syndromes, chronic inflammatory bowel disease, history of 
colorectal polyps or cancer, or previous bowel resection, were excluded. 
Presence of symptoms and related comorbidities has always been collected in 
the database. 
 
Then we set up a telephone questionnaire in order to retrieve 
information on smoking habits, BMI, physical activity, diet, alcohol 
consumption, family history and usage of low-dose Aspirin. A data-manager 
created an ad hoc database using Microsoft Access 2007.  
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All patients were then interviewed by me by telephone in order to 
collect information on their lifestyle, family history of colorectal neoplasia 
and use of low-dose Aspirin. Patients were also asked if they had undergone 
an endoscopy before their first screening colonoscopy.  
 
In Table 2.1 the exact telephone questionnaire (originally in Italian) 
used to collect information and fill in the database is reported. The average 
duration of a phone-call was about 3.5 minutes, and the average number of 
attempts to reach an individual was 1.3. 
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Table 2.1 Telephone questionnaire 
  
1)    Height in cm
2)    Weight in kg (preferably at the time of colonoscopy or typical weight otherwise)
3)    How would you define your job (or your typical work day)?
Sedentary
Necessitating mild-to-moderate physical activity
Necessitating strong physical activity
4)    In your spare time, do you regularly practice physical activity / sport?
Yes
No
5)    With regard to smoking, at the time of your first colonoscopy, you were:
Current smoker (at the colonoscopy o up to 12 months before)
Ex-smoker (stopped at least 12 months before colonoscopy)
Never smoker
For smokers and ex-smokers only: 
6)    During your smoking years, what was your average number of cigarettes smoked?
7)    When did you start smoking?
For ex-smokers only: 
8)    When did you stop smoking? 
9)    Have you ever drunk an alcoholic beverage?
Yes
No
If 9 is yes:
10)  Think about the last 7 days: how many days did you happen to drink any alcoholic beverage?
Values 0-7
If 10 is 1 or more:
11)  How many drinks of alcoholic beverages have you drunk on average in those drinking days?
Value
12)  How many meals of fruit or vegetables do you usually eat?
Value
13)  Has any of your relatives ever been diagnosed with a colorectal neoplasia?
Indicate the most severe among the following:
I grade CCR (<60 years old)
I grade CCR (≥ 60 years old)
II grade CCR
Adenomas only
No family history 
14)  At the time of your first colonoscopy, were you using daily low-dose aspirin?
Yes
No
If 14 is yes:
15)  Since when?
Age at start
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 Ninety-five patients out of 870 (10.9%) were not interviewed for 
various reasons: 70 (8.0) cases were not reachable by telephone, 5 (0.6%) 
refuse to answer the questionnaire, 6 (0.7%) died between the date of their 
first colonoscopy and the date of phone call. Moreover, 14 (1.6%) individuals 
stated that they had undergone one or more colonoscopy before their first 
screening colonoscopy and the questionnaire was discontinued (Figure 2.2). 
 
Figure 2.2 Flowchart 
 
 
 
 
 
 
 
 
 
 
 
 
 Individuals who answered the questionnaire were similar to the 
individuals who did not in terms of outcome of the first colonoscopy, as 
shown in Table 2.2. 
870 
775 under consideration 
70 unreachable by phone 
5 did not want to answer 
6 deaths 
14 previous colonoscopy 
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Table 2.2. Most severe outcome at first colonoscopy 
 
 
 IN OUT  
Outcome No. (%) No. (%) P-valuea 
No adenoma 227 (29.3) 23 (24.2) 0.28 
Low-risk Adenoma  133 (17.2) 34 (35.8)  
High-risk Adenoma 351 (45.3) 33 (34.7)  
Invasive tumour 64 (8.3) 5 (5.3)  
Total 775 95 
 
 
aMantel-Haenszel Chi-square test for trend 
 
 
  
15 
 
2.3 Statistical methods 
 
 We used a variety of statistical methods to analyze the data for this 
project. We will describe in details each of the methods - and report the 
appropriate literature references - when its applications and corresponding 
results will be reported along the next chapters. Briefly, we used the following 
statistical methods. 
 
• Simple descriptive and univariate analyses: both the Chi-square test 
and the Chi-square test for trend were used to explore the associations 
between outcome (endoscopic finding) and individuals’ characteristics. 
• Multivariable logistic regression and its extension to the multinomial 
multivariable logistic regression were used to identify independent risk 
factors.  
• “Spike at zero” functions, based on fractional polynomials, were used 
to estimate the dose–response function for continuous exposures in 
circumstances where there was a certain percentage of unexposed 
individuals (i.e. never smokers). 
• A multivariable linear predictor was computed to assign to each patient a 
Risk Score predicting the probability of poor endoscopic outcome. 
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• A Nomogram was built to map the predicted probabilities of poor 
endoscopic outcome into points on a scale from 0 to 100 in a user-
friendly graphical interface. 
• We finally applied Homogeneous Markov Models to simultaneously 
model the disease process over time, and evaluate the effect of lifestyle 
and other characteristics on each transition from one state to another. 
 
Descriptive, univariate and multivariable logistic regression analyses were 
carried out with the SAS software (SAS Institute, Cary, NC). The Nomogram 
and the Markov Models analysis were computed using the R (http://cran.r-
project. org/) software. For the “Spike at zero” functions we used both the R 
software and the STATA (College Station, TX, USA) software. 
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3. Risk factors at the first colonoscopy 
 
 In this chapter we will evaluate whether lifestyle factors, gender, family 
history and low-dose Aspirin have an impact on the detected neoplasia at the 
first screening colonoscopy. If a statistically significant association between 
those factors and the detected neoplasia is demonstrated, important 
conclusions will be drawn. Those factors should indeed be considered when 
deciding on the age at which CRC screening should begin, either lowering the 
age in the bad prognostic group (high-risk of neoplasia) or increasing the age 
in the good prognostic group (low-risk of neoplasia).  
 
 
3.1 Descriptive and univariate analysis 
 
 In order to synthesize the information regarding all the observed 
outcomes, from normal mucosae to invasive tumors (Table 3), we identified 
and grouped the endoscopic findings which should be considered at high risk 
of developing a CRC (high-risk adenomas). The 2006 guideline on 
postpolypectomy surveillance of the United States Multi-Society Task Force 
(MSTF) on CRC will be used to distinguish two main types of adenomas: (1) 
low-risk adenomas, defined as 1–2 tubular adenomas < 10 mm, and (2) high-
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risk adenomas, defined as adenoma with villous histology, high-grade 
dysplasia, ≥ 10 mm, or 3 or more adenomas15. We then grouped the invasive 
tumors together with the high-risk adenoma to form the high-risk neoplasia 
category.  
 
Table 3.1. Most severe outcome at first colonoscopy in details 
 
Outcome No. (%) 
Normal Mucosae 43 (5.5) 
Non-oncological alteration 148 (19.1) 
Non-adenomatous polyp 36 (4.6) 
Low-risk Adenoma <10 mm a  133 (17.2) 
High-risk Adenoma <10 mm 99 (12.8) 
Adenoma 10-19 mm 193 (24.9) 
Adenoma ≥ 20 mm 59 (7.6) 
Invasive tumour 64 (8.3) 
Total 775 
 
a One or two adenomas < 10 mm with no villous component and no evidence of high-
grade dysplasia 
 
 
 
 The outcomes reported in Table 3.1 are the detailed colonoscopy 
outcomes of the 775 patients who answered the questionnaire. One-hundred 
and ninety-one individuals (24.6%) had no polyps (non-oncologic alterations 
were mainly hemorrhoids and diverticula); 36 had non-adenomatous 
(hyperplastic in the vast majority) polyps. A patient was classified in the 
High-risk 
adenoma 
High-risk 
neoplasia 
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category “low-risk adenoma”  if  his/her endoscopic finding was one or two 
adenomas < 10 mm in diameter with no villous component and no evidence of 
high-grade dysplasia; patients with 3 or more adenomas, or at least one 
adenoma bigger than 10 mm or with villous component or with high-grade 
dysplasia were classified in the category “high-risk adenoma”  (n=351, 
45.3%). Finally, 64 (8.3%) patients were found with an invasive neoplasia, 20 
(2.6%) of them were diagnosed as adenocarcinoma in a polyp (i.e. cancerous 
polyp), while 44 (5.7%) were proper invasive tumors. Forty-two of them were 
adenocarcinomas, 1 was a neuroendocrine tumor and one was a spinocellular 
carcinoma. All the 44 patients with invasive tumors underwent radical surgery 
and received adjuvant treatment according to the stage of the disease. 
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Table 3.2. Characteristics of population and prevalence of high-risk neoplasia 
at first colonoscopy 
 
 Categories No. (col %) 
High-risk  
Neoplasia 
No. (row %) 
P 
All individuals  775 (100.0) 415 (53.5)  
Gender Male 400 (51.6) 250 (62.5) <0.01 Female 375 (48.4) 165 (44.0) 
Age 
50-60 268 (34.6) 133 (49.6) 
0.11 61-67 296 (38.2) 162 (54.7) 
68-74 211 (27.2) 120 (56.9) 
Family history a 
None 667 (87.6) 358 (52.9) 
0.08 
0.02 b 
2nd grade  - CRC 23 (3.0) 10 (43.5) 
1st grade - CRC ≥ 60 years 53 (6.9) 30 (56.6) 
1st grade - CRC < 60 years 20 (2.6) 16 (80.0) 
Physical activity  
Weak 303 (39.1) 180 (59.4) 
<0.01 Moderate 206 (26.6) 111 (53.9) 
Strong 266 (34.3) 124 (46.6) 
BMI 
< 25.0 (Normal weight) 366 (47.2) 194 (53.0) 
0.50 25.0-29.9 (Overweight) 311 (40.1) 177 (56.9) 
≥ 30.0 (Obese) 98 (12.7) 44 (44.9) 
Smoking status 
Never smoker 353 (45.6) 172 (48.7) 
<0.01 Former smoker 228 (29.4) 124 (54.4) 
Current smoker 194 (25.0) 119 (61.3) 
Smoking  
(pack-years) 
0 353 (45.6) 172 (48.7) 
<0.01 
1-15 76 (9.8) 35 (46.1) 
16-30 133 (17.2) 76 (57.1) 
31-40 94 (12.1) 55 (58.5) 
> 40 119 (15.4) 77 (64.7) 
Alcohol intake a 
(grams/day) 
0 316 (41.0) 151 (47.8) 
<0.01 0.1-12.4 145 (18.8) 67 (46.2) 12.5-24.9 133 (17.2) 77 (57.9) 
≥ 25.0 177 (23.0) 117 (66.1) 
Fruit and vegetable 
 intake (meals per day) a 
≤ 2 225 (29.5) 137 (60.9) 
<0.01 3-4 368 (48.2) 206 (56.0) 
≥ 5 171 (22.4) 62 (36.6) 
Daily low-dose Aspirin a 
Never user 661 (86.4) 360 (54.5) 0.08 
0.02 c ≤ 5 years 49 (6.4) 30 (61.2) 
> 5 years 55 (7.2) 21 (38.2) 
 
a
 Some patients had missing values; b 1st grade - CRC < 60 years vs others; c > 5 years vs 
others. 
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 We reported in Table 3.2 the characteristics of the 775 individuals who 
answered the questionnaire. The study population was divided almost equally 
between men and women. The majority of the patients declared no family 
history and only 20 patients out of 775 (2.6%) reported a family history of 
CRC in a first-degree relative who was diagnosed under the age of 60 years. 
Typical work day and sports were combined in one variable, physical activity, 
expressed in three categories: weak if the individual declared to lead a 
sedentary life; moderate if the individual declared to do mild to moderate 
physical activity during his/her work day and no sports; strong otherwise. A 
few patients were obese. With regard to smoking, 353 individuals declared 
they never smoked (45.6%), while 194 declared to be “current smokers” at the 
time of their colonoscopy. With regard to alcohol drinking, 316 individuals 
declared to be teetotalers (41.0%) while 177 (23.0%) to drink at least 2 drinks 
per day. We used grams per day (g/day) as a standard measure of ethanol 
intake, 12.5 grams being the standard alcohol intake per drink of any alcoholic 
beverage. Moreover 225 (29.5%) people reported a low intake of fruit and 
vegetables (2 or less meals per day). Finally, 55 (7.2%) individuals had been 
taking low-dose Aspirin for more than 5 years before the colonoscopy. Five 
years is the length of time that has been recognized to have a clear protective 
effect on CRC13. 
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 We observed 415 patients presenting with a high-risk neoplasia (high-
risk adenoma or invasive neoplasia). At the univariate analysis, male gender, 
high-risk family history (first grade relative diagnosed with CRC at a young 
age), low physical activity and low fruit/vegetable intake were associated with 
a higher risk of high-risk neoplasia. A long-term use of daily low-dose Aspirin 
was associated with a low prevalence of high-risk neoplasia, while a short-
term use of daily low-dose Aspirin was associated with prevalence of high-
risk neoplasia similar to the one observed for the never users. As for the 
smoking habit and alcohol intake, the association was statistically significant, 
but a clear increase in risk was not observed for low consumption of neither 
tobacco nor alcohol. 
  
 Prevalence of high-risk neoplasia did not increase significantly as the 
age increased. This could be explained by the fact that, despite age is a well-
known risk factor for CRC, the age range in our population was quite narrow 
(50-74 years) and only little variation in risk could be observed. Neither BMI 
was statistically associated with the risk of high-risk neoplasia. The lack of 
association between BMI and high-risk neoplasia was quite surprising, since 
high BMI is a well known risk factor for CRC. So how can we possibly 
explain the absence of association reported in this analysis? We hypothesized 
that patients with a high BMI (e.g. >25) are at higher risk of hemorrhoids and 
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diverticula compared to patients with a lower BMI. Moreover, we must 
remember that all the individuals of this study population had a previous 
positive FOBT, which can be associated with the presence of hemorrhoids and 
diverticula. All this could have lead to an over-representation of the 
population with high values of BMI in the “No polyps” reference outcome 
category, this causing to a dilution of the effect of BMI on the risk of high-risk 
neoplasia. 
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3.2 Multinomial multivariable logistic regression 
 
Multinomial logistic regression is the extension for the binary logistic 
regression when the categorical dependent outcome has more than two 
levels16. Consider a random variable Yi that may take one of several discrete 
values, which we index 1,2,…,J. In our case, the response is a recategorization 
of “most severe outcome at first colonoscopy” (see Table 3.3) taking the 
values J=1 for the categories “Normal mucosae”, “Non-oncological 
alteration” and “Non adenomatous polyp”, J=2 for “Low-risk adenoma” and 
J=3 for “High-risk adenoma” and “Invasive neoplasia”.  
 
 
Table 3.3. Recategorization of the outcome in three categories 
Category (J) Finding at colonoscopy 
1 
Normal mucosae 
Non-oncological alteration 
Non-adenomatous polyp 
2 Low-risk adenoma 
3 
High-risk adenoma 
Invasive neoplasia 
 Total 
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This recategorization of the outcome led to comparable frequencies among the 
categories and has a clinical significance.  
 
Let  
 
 
 
 
denote the probability that the i-th response falls in the j-th category. In the 
example pii1 is the probability that the i-th respondent resulted in a normal 
mucosae or non-oncological alteration or non-adenomatous polyp. 
 
 We now consider models for the probabilities piij. In particular, we 
would like to consider models where these probabilities depend on a vector Xi 
of covariates associated with the i-th individual or group. We nominate one of 
the response categories as a baseline or reference cell, calculate log-odds for 
all other categories relative to the baseline, and then let the log-odds be a 
linear function of the predictors. We pick the first category as a baseline 
(normal mucosae or non-oncological alteration or non-adenomatous polyp). In 
the multinomial logit model we assume that the log-odds of each response 
follow a linear model 
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where αj is a constant and βj is a vector of regression coefficients, for j = 2, 
3…J (in our analysis for j=2 and 3, as 1 is the reference category). 
This model is analogous to a logistic regression model, except that the 
probability distribution of the response is multinomial instead of binomial and 
we have J-1 equations instead of one.  
 
 The multinomial logit model may also be written in terms of the 
original probabilities piij rather than the log-odds.  
 
 
 
Note that the convention ηi1 = 0 makes this formula valid for all j.  
 
 To describe smoking, we used the pack years of smoking for the 
tobacco exposure, calculated as the mean number of packs smoked per day 
multiplied by the number of years that the patient smoked. We used a standard 
categorization of pack years, i.e. 0, 1-15 and >15, because 15 years of 
smoking (corresponding to 15 years of pack years on average) are thought to 
be necessary to cause major DNA damages that lead to polyps14. 
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In Table 3.4 we reported the results from the multivariable multinomial logistic 
regression analysis 
 
Table 3.4. Multivariable multinomial logistic regression analysis for high-risk 
neoplasia 
 
  
Type of 
neoplasia OR (95% CI) P
a
 
Gender Male vs female 
Low-risk 1.04 (0.65 - 1.66) 
<0.01 
High-risk 1.79 (1.20 - 2.68) 
Family history 
1st grade - CRC 
< 60  
years vs others 
Low-risk 1.08 (0.15 - 7.89) 
0.14 
High-risk 3.32 (0.72 - 15.35) 
Physical activity 
Moderate vs 
Weak 
Low-risk 0.69 (0.39 - 1.23) 
0.91 
High-risk 0.71 (0.44 - 1.16) 
Strong vs Low 
Low-risk 0.75 (0.44 - 1.28) 
0.37 
High-risk 0.61 (0.38 - 0.97) 
Pack-years of smoking 
15.1-30 vs ≤ 15 
Low-risk 1.77 (0.99 - 3.17) 
0.43 
High-risk 1.46 (0.87 - 2.44) 
>30 vs ≤ 15 
Low-risk 2.23 (1.25 - 3.99) 
0.96 
High-risk 2.21 (1.33 - 3.66) 
Alcohol  
(grams/day) 
12.5-24.9 vs 
<12.5 
Low-risk 1.10 (0.60 - 2.03) 
0.35 
High-risk 1.41 (0.83 - 2.38) 
≥ 25 vs <12.5 
Low-risk 0.97 (0.53 - 1.80) 
0.03 
High-risk 1.73 (1.05 - 2.87) 
Fruit and vegetable  
intake (meals per day) 
3-4 vs ≤ 2 
Low-risk 0.87 (0.50 - 1.50) 
0.91 
High-risk 0.89 (0.55 - 1.43) 
> 4 vs ≤ 2 
Low-risk 0.48 (0.26 - 0.90) 
0.18 
High-risk 0.33 (0.19 - 0.57) 
Daily low-dose 
Aspirin usage 
≤ 5 years vs 
Never user 
Low-risk 0.51 (0.19 - 1.38) 
0.36 
High-risk 0.77 (0.36 - 1.65) 
> 5 years vs 
Never user 
Low-risk 0.42 (0.19 - 0.91) 
0.40 
High-risk 0.30 (0.15 - 0.58) 
 
aWald test, testing homogeneity of odds ratios between low and high-risk 
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 The Wald test evaluates whether or not the independent variable is 
statistically significant in differentiating between the two categories in each of 
the embedded binary logistic comparisons. For example, when we compared 
high intake (>4 meals of fruits and vegetables) versus low intake (≤2 meals) 
we obtained β2=-0.729 for low-risk adenomas and β3=-1.1152 for high-risk 
adenomas. Given β2-β3=0.386, VAR(β2)=0.102, VAR(β3)=0.078 and 
COV(β2,β3)=0.049 we can calculate VAR(β2,β3)= 0.102+0.078-
2(0.049)=0.082 and a standardized normal empirical value of 1.349, which 
corresponds to a 2 sided p-value of 0.177. We accept the null hypothesis that 
high versus low intake of fruits and vegetables has the same protective effect 
on the prevalence of low-risk adenomas (category 2) and high-risk adenomas 
(category 3).  
  
 A very interesting result is that high intakes of alcohol (2 drinks per day 
or more) and male gender have a differential association with low-risk 
adenomas and high-risk adenomas. Drinking 2 drinks per day or more and 
being a man seem to decrease the time latency from normal mucosae to high-
risk adenoma or from low-risk adenoma to high-risk adenoma. If we had used 
only the classical binary logistic regression we would have missed this 
important information (see Table 3.5). 
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Table 3.5. Multivariable logistic regression analysis 
 
Variable Comparison High-risk neoplasia 
  OR  (95% C.I.) 
Gender Male vs female 1.76 (1.27 - 2.45) 
Family history 1
st
 grade - CRC < 60 years  
vs others 3.24 (1.04 - 10.12) 
Physical activity 
Moderate vs Low 0.86 (0.59 - 1.27) 
High vs Low 0.71 (0.48 - 1.03) 
Smoking  
(pack-years) 
15.1-30 vs ≤ 15 1.10 (0.73 - 1.65) 
>30 vs ≤ 15 1.46 (1.00 - 2.14) 
Alcohol  
(grams/day) 
12.5-24.9 vs <12.5 1.33 (0.87 - 2.01) 
≥ 25 vs <12.5 1.73 (1.16 - 2.59) 
Fruit and vegetable 
(meals per day) 
3-4 vs ≤ 2 0.97 (0.67 - 1.40) 
> 4 vs ≤ 2 0.46 (0.29 - 0.73) 
Daily low-dose  
Aspirin usage 
≤ 5 years vs Never user 1.05 (0.55 - 1.99) 
> 5 years vs Never user 0.44 (0.24 - 0.80) 
 
 
 
 The final multivariable model is reported in Table 3.5. We went back to 
the simple binary outcome, because the primary aim of our project is to 
evaluate which factors are associated with the risk of high-risk neoplasia. The 
model showed that men had a 76% risk increase of having a high-risk 
neoplasia compared to women. As expected, individuals with a high-risk 
profile of family history (i.e. individuals who had a first grade relative 
diagnosed with CRC at a young age) were characterized by a more than three-
fold increase in risk of high-risk neoplasia when compared to individuals with 
no family history or low-risk family history. A long-term consumption of low-
dose Aspirin was associated with a statistically significantly reduced risk of 
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high-risk neoplasia, confirming recent published evidence13,14. All modifiable 
lifestyle factors were statistically associated with the risk of high-risk 
neoplasia (with the exception of physical activity which showed a borderline 
statistically estimate; OR=0.71 with 95% confidence interval 0.48 - 1.03). All 
these significant associations represent probably the most important finding in 
the first phase of our analysis, because we provided strong evidence that 
supports the role in CRC risk of physical activity, diet, smoke and alcohol 
habits, and medication use, which all are potentially modifiable factors. 
Moreover, all these factors should probably be considered in the decision 
process about the age at which CRC screening should begin, either by 
lowering the age in individuals with a poor lifestyle or increasing the age in 
individuals with a healthy lifestyle. 
3.3 “Spike at zero” functions 
 
A common task in epidemiology is to estimate the dose–response 
function for a continuous exposure. Spike at zero functions17 can be used 
when there is a certain percentage of unexposed individuals. Typical examples 
are cigarette consumption, alcohol intake, or occupational exposures. The 
subjects who are not exposed may be characterized by unknown or 
uncollected factors which might be associated to outcome in the study. A 
classical example is represented by the association between alcohol and 
cardiovascular diseases: a percentage of non drinkers might avoid alcohol 
because of their health conditions, this leading to slightly decreased risk of 
disease in moderate drinkers compared to non drinkers. For this reason it is 
useful to analyze separately exposed and not exposed, albeit within the same 
model. Any model of continuous exposure variables – i.e. fractional 
polynomials (FP) and spline functions - could be extended to allow for a 
proportion of unexposed individuals. 
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Fractional Polynomial-based “Spike at zero” function 
 
 Royston and Altman18 introduced and formalized the fractional 
polynomial (FP) models in 1994. A first-order fractional polynomial (FP1) is 
written as: 
 
, 
 
while a second-order fractional polynomial (FP2) is written as: 
 
, 
 
and so on. The powers p are chosen from a restricted set, S = {−2, −1, −0.5, 0, 
0.5, 1, 2, 3}. 
 
Assume that x≥0 for all individuals. In order for FP functions of x to be 
defined at x=0, the origin of x is shifted by adding a small constant, c, before 
analysis. By default, we take c as the smallest difference between successive 
positive values of x17. Consider a model whose linear predictor, η, is given by: 
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The linear predictor η is a FPm function of x+c when x>0 and a constant (β) 
when x=0. Thus η is a discontinuous function of x with a possible jump at 
x=0. For a first-grade FP, we can re-write the expression for η as: 
 
 
 
where: 
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As reported by Royston et al. in their paper17: 
 
“The FSP-spike procedure for selecting a model has two stages. 1. In the first 
stage, the most complex model comprising z and the best FP2+(x+c;p1,p2) is 
compared with the null model on 5 d.f. (4 d.f. from the best FP2 model plus 
one from the binary z term). If the test is significant, the steps of the FSP for 
selecting an FP function are followed, but with z always included in the 
model. If the test is not significant, stop, concluding that the effect of x is ‘not 
significant’ at the alfa level. Otherwise continue. Test FP2+(x+c;p1,p2) 
against the best straight line at the alfa level using 3 d.f. If the test is not 
significant, stop, the final model being a straight line. Otherwise continue. 
Test FP2+(x+c;p1,p2) against the best FP1+(x+c;p1) at the alfa level using 2 
d.f. If the test is not significant, the final model is FP1, otherwise the final 
model is FP2. End of the procedure.  
2. In the second stage (performed separately), z and the remaining FP or 
linear component are each tested for removal from the model. If both parts 
are significant, the final model includes both; if one or both parts are non-
significant, the one with the smaller deviance difference is removed. In the 
latter case, the final model comprises either the binary dummy variable or the 
selected FP function. If only an FP function is selected, the spike at zero plays 
no further part. Since the selection of an FP function may be affected by the 
presence of the binary dummy variable, the resulting model may differ from 
that from a standard FP analysis”. 
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FSP-spike procedure for alcohol 
 
First Stage: function selection procedure: determine the ‘best’ function from 
the FP class 
  Deviance 
Distance to 
Dev(FP2+Z) d.f. P Power(s) 
null 1065.187 25.397 5 0.000   
lin+Z 1048.904 9.114 3 0.028 1 
FP1+Z 1043.364 3.574 2 0.167 0 
FP2+Z 1039.790  -      1, 3 
 
 
FP2+Z was not statistically better than FP1+Z. Therefore, at the first stage we 
chose FP1+Z. 
 
 
Second Stage: z and the chosen FP are each tested 
  Deviance 
Distance to 
Dev(FP1+Z) d.f. P   
FP1+Z 1043.364  -      0 
FP1 (Dropping Z) 1048.872 5.508 1 0.019 0 
Z (Dropping FP1) 1058.311 14.947 2 0.001   
 
 
Both terms were significant. We accepted to keep FP1+z as the final model 
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If we compare AIC of the selected spike function with the one of the best FP1 
we obtain: 
 
Model AIC d.f. Power 
FP1 + z 1048.4 3 0 
FP1 + 1050.6 2 0.5 
 
 
 
AIC is a criterion for selecting an optimum model in a class of nested and 
non-nested models or models fitted on different samples. It takes into account 
both the binomial deviance and the degrees of freedom of each model and was 
defined as: 
 
AIC(m)= - 2L(m) + 2k(m)  
 
where L(m) is the maximum log-likelihood for the m model and k(m) is the 
number of predictors for the m model. Better models have smaller AIC. 
 
 
 
So the best model was the spike function model, which can be written as: 
Logit[(P(Outcome=High Risk Neoplasia)]= -0.8901+ (Z) 0.8014 + (1-Z) 
0.4495 log(Grams/day) 
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So, for example: 
a) Non drinkers  
LOGIT[P(Outcome=High Risk Neoplasia)]= - 0.0887 
P(Outcome=High Risk Neoplasia)=exp(-0.0887)/1+exp(-0.0887)=0.48 
 
b) Drinkers of 40 grams /day 
LOGIT[P(Outcome=High Risk Neoplasia)]= -0.8901+0.4495 LN(40)=0.768 
P(Outcome=High Risk Neoplasia)= exp(0.768)/1+exp(0.768)=0.68 
 
 
Figure 3.1. Association between alcohol and high-risk neoplasia; spike at zero 
function, FP1+ and p1=0 
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 For non-drinkers, there was a probability of 0.48 (95% CI 0.42-0.53) of 
having a colorectal high-risk neoplasia detected at their first colonoscopy. 
Light drinkers (<12.5 grams/day i.e. 1 drink per day) did not seem to have a 
higher risk of colorectal neoplasia compared to non-drinkers. When 
considering the lower doses, the FP1 function was steeply increasing with 
increasing number of grams/day, then a lessening increase rate is shown 
(Figure 3.1). 
Noteworthy, the chosen spike at zero function (FP1+z, p1=0) had a better 
relative goodness of fit (AIC=1048.4) when compared with the best plain FP1 
model (p=0.5; AIC = 1050.6). We can therefore hypothesize that a proportion 
of non-drinkers might avoid alcohol because of some health conditions linked 
to the endpoint of interest. 
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FSP-spike procedure for smoking 
 
  Deviance 
Distance to 
Dev(FP2+Z) d.f. P Power(s) 
null 1068.937 14.145 5 0.015   
lin+Z 1063.142 8.35 3 0.039 1 
FP1+Z 1058.538 3.746 2 0.154 0 
FP2+Z 1054.792  -      1, 2 
 
FP2+Z was not statistically better than FP1+Z. Therefore, from the first stage 
we chose FP1+Z. 
 
  Deviance 
Distance to  
Dev(FP1+Z) d.f. P  Power(s) 
FP1+Z 1058.538  -      0 
FP1 (Dropping Z) 1060.846 2.308 1 0.129 0 
Z (Dropping FP1) 1066.133 7.595 2 0.022   
 
 
FP1+Z was not better than FP1, therefore we drop the spike at zero model. 
Only the FP function was selected, as the spike at zero plays no further part. 
In confirmation of this, the AIC of the spike model is higher than the AIC of 
the simple best FP1.  
 
Model AIC d.f. Power 
Best FP1  + z 1064.5 3 0 
Best FP1+  1063.5 2 0.5 
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So the best model was the FP1+ function model with power=0.5, which can be 
written as: 
 
Logit[P(Outcome=High Risk Neoplasia)]= -0.0635+ 0.0699 (Pack-years)0.5 
 
 
 
 
Figure 3.2. Association between pack-years of smoking and high-risk 
neoplasia. FP1+, p1=0.5 
 
  
 
 
 
As shown in the Figure 3.2, there was an increasing prevalence of high-risk 
neoplasia with increasing number of pack-years.  
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3.4 Linear predictor - risk score 
 
 We then wanted to build a unique linear predictor, an individual risk 
score, based on the information deriving from all the studied variables. At the 
multivariable level, we modeled age and fruit/vegetables consumption as 
continuous variables and assumed a linear relationship between those 
covariates and the log-odds of high-risk neoplasia. Then, since the advantage 
of a spike at zero function for alcohol was no longer significant at a 
multivariable level, we used the best first-order fractional polynomial function 
(i.e. the one with power=0.5) to evaluate the association between alcohol and 
the log-odds of high-risk neoplasia. The same first-order fractional polynomial 
function was used for smoking. Gender was used as dichotomous variable, as 
well as family history, as described in the table below. Physical activity was 
used in three categories and therefore two dummy variables were used in the 
model. Since in the previous analysis the Aspirin effect was evident after a 
long-term consumption (see Table 7), we dichotomized the variable in > 5 
years of consumption versus ≤ 5 years (the latter category including the never 
users). 
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We hereafter report the final linear predictor of the log-odds of high-risk 
neoplasia: 
  
Logit [Pr(Oucome=High Risk Adenoma)] =  
 
 
 
 
The risk of finding a high-risk neoplasia at the first screening colonoscopy 
significantly increased with increasing alcohol consumption, pack-years of 
smoking (borderline significant) and decreased with increasing fruit and 
vegetables consumption. Male gender and high-risk profile of family history  
were associated with an increased risk of high-risk neoplasia, while long-term 
consumption of low-dose Aspirin and strong physical activity were associated 
with decreased risk of high-risk neoplasia. Age was not statistically associated 
with the risk of high-risk neoplasia. 
Variable Description Parameter estimates P-value
Intercept -0.083 0.9238
Age  Continuous +0.009 0.4933
Gender M=1; F=0 +0.557 0.0009
Family History 1st grade < 60 yrs = 1; others=0 +1.211 0.0391
Moderate phisical activity Yes=1; No=0 -0.217 0.2846
Strong phisical activity Yes=1; No=0 -0.376 0.0535
Smoking (pack-years) Continuous +0.038 0.0649
Alcohol (grams/day) Continuous +0.375 0.0076
Fruit/vegetables meals/day Continuous -0.221 0.0007
Low-dose aspirin > 5 years = 1; others=0 -0.859 0.0036
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Model accuracy 
 
 
 Evaluating the model accuracy, that is assessing the model's ability to 
accurately fit the data, is a critical step in the modelling process to guarantee 
robust estimates calculations. We used an internal validation of predictive 
logistic regression models for the decision-making based on the evaluation 
of both discrimination and calibration19. Discrimination refers to the correct 
relative ranking of predicted probabilities of a specific event, whereas 
calibration describes whether predicted probabilities are too high or too low 
relative to true population values. 
 
 
Discrimination 
 
 A widely accepted measure of discrimination ability of a predictive 
model is the c-index (for concordance), which applies to predictions that are 
continuous, dichotomous, ordinal, and censored time-to-event outcome 
predictions20. In binary cases, c-index is equivalent to the area under the 
Receiver Operating Characteristic (ROC) curve, which is a common method 
of measuring the predictive ability of logistic regression models.  
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The curve is constructed by varying the cut-point that determines which 
estimated event probabilities are considered to predict the event. The curve 
plots the proportion of incorrectly predicted outcomes (1-specificity) on the 
x-axis and the proportion of correctly predicted outcomes (sensitivity) at a 
given cut-point on the y-axis. The area under a ROC curve (c-index), which 
ranges from zero to one, provides a measure of the model's ability to 
discriminate between those subjects who experience the outcome of interest 
(high-risk neoplasia) versus those who did not. The greater the area under the 
ROC curve the better the model's discriminatory power.  
  
 We used the ROCCONTRAST statement in SAS to implement the 
non-parametric approach of DeLong, DeLong, and Clarke-Pearson to 
compare ROC curves21. When two curves are constructed based on 
regression models performed on the same individuals, statistical analysis on 
differences between curves must take into account the correlated nature of 
the data. DeLong et al. presented a nonparametric approach to the analysis of 
areas under correlated ROC curves. 
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Figure 3.3. ROC curves 
 
 
 
 
We built two models, the first named “ROC1” and the other “Model”. The 
first one derived from a multivariable logistic regression model including 
age, gender and family history as covariates. These three variables are the 
most recognized risk factors of CRC10. The second one derived from a 
multivariable logistic regression model including age, gender, family history 
plus all the lifestyle factors and low-dose Aspirin use. 
      
We then calculated the area under the ROC curve for the two models and built 
a test to compare ROC curves. 
1) C-index for all variables (“Model”): 0.678  
2) C-index for known risk factors (“ROC1”): 0.616 
3) ROC Contrast Test Results; Chi-Square=12.7; P<0.001 
 
ROC values of around 0.7 are considered to indicate a good discriminating 
model18. Therefore both models had good discrimination ability. But, given 
the results from the ROC Contrast Test, we could conclude that the modifiable 
lifestyle factors adds additional information to the model with only age, 
gender, and family history (ROC1) in distinguishing between patients who 
were diagnosed with high-risk neoplasia and those who were not.  
 
  
47 
 
Calibration  
 
Calibration refers to whether the predicted probabilities agree with the 
observed probabilities.  
 
Figure 3.4. Probability of high-risk neoplasia at first screening colonoscopy 
according to quintiles of the linear predictor: observed versus expected 
 
 
 
 
We evaluated the calibration of the logistic regression models using the  
Hosmer–Lemeshow test16.  We used quintiles to re-categorize the distribution 
of expected and observed probabilities. 
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Hosmer–Lemeshow test calculation 
 
 
 
 
 Since Hosmer–Lemeshow test was not significant we could not reject 
the null hypothesis that observed and expected values are the same, so we 
were lead to conclude that the model fits the data well.  
 The test has several limitations22. The test can be very sensitive to small 
fit discrepancies observed in very large samples, but it was not our case. Also, 
the results of the test depend on the number of groups specified (five in the 
example) as well as the distribution of the linear predictor values within this 
group. Therefore, we tried to overcome this problem by repeating the test 
using 4, 8 and 10 categories, and the Hosmer–Lemeshow test was never 
significant. 
 
 
 
Quintile N Obs Events
Exp 
Events
Obs 
Probabili
ty
Exp 
Probabili
ty
W= Exp 
Probability /       
(1-Exp 
Probability)
Obs 
Events - 
Exp 
Events
(Obs Events - 
Exp Events) ˆ 
2
[(Obs Events - 
Exp Events) ˆ 2] 
/ W
1 152 42 49.8 0.28 0.33 0.22 -7.78 60.53 1.81
2 153 67 66.7 0.44 0.44 0.25 0.32 0.10 0.00
3 153 93 80.6 0.61 0.53 0.25 12.45 154.89 4.06
4 153 94 95.5 0.61 0.62 0.23 -1.50 2.26 0.06
5 153 112 115.5 0.73 0.75 0.19 -3.48 12.14 0.43
TOTAL 764 408 408 Chi-square 6.36
P-value 0.10
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3.5 Nomogram 
 
Nomograms are widely used for cancer prognosis, primarily because of 
their ability to reduce statistical predictive models into a single numerical 
estimate of the probability of an event, such as death or recurrence, that is 
tailored to the profile of an individual patient. We transferred the use of the 
nomogram to a screening setting because, to our opinion, it might provide 
practical and useful information to the general practitioner and 
gastroenterologist/endoscopist in order to decide whether a patient should 
undergo such an invasive exam as the colonoscopy or could be submitted to 
other less invasive exams, such as sigmoidoscopy or rectoscopy. 
  
 Nomograms may convey the results of a variety of statistical models. In 
our case, the intention was to predict a binary outcome, i.e. the 
presence/absence of high-risk neoplasia at colonoscopy, by using gender, 
physical activity, diet, smoking (pack years), alcohol consumption, use of 
low-dose Aspirin as independent variables. 
 
A guide on how to build and interpret a nomogram can be found in the 
2008 article by Alexia Iasonos et al.23 and the R (http://cran.r-project.org/) 
software recently provided the function called nomogram in the rms package, 
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which easily conveys the results of any statistical model to a graphical 
representation. 
 
 The usefulness of a nomogram is that it maps the predicted 
probabilities into points on a scale from 0 to 100 in a user-friendly graphical 
interface. The total points accumulated by the various covariates correspond 
to the predicted probability of event for a patient (Figure 3.5).  
Figure 3.5. The nomogram 
Points
0 10 20 30 40 50 60 70 80 90 100
Age (Years)
50 58 66 74
Gender
Female
Male
Family history
Low / no risk
 High risk
Physical activity
High Low
Moderate
Smoking (Pack-years)
0 20 40 60 80 120 160
Alcohol (Drinks/day)
0 0.5 1 1.5 2 2.5 3 3.5 4 4.5 5 5.5
Fruit and vegetable (Meals/day)
6 4 2
5 3 1
Daily low-dose aspirin usage
 > 5 years 
< 5 years 
Total Points
0 50 100 150 200 250 300 350 400
High Risk Neoplasia Probability (%)
12 20 30 40 50 60 70 80 90 92
 To explain the use of it, we can say that a patient who smokes 1 
pack/day for 20 years acquires around 15 points, whereas a patient who has 
never smoked got 0 points. Males acquire 10 points, while women acquire 0 
points. And so on. By summing the points of all the characteristics, one gets 
the individual total points, which can be converted to the predicted probability 
of finding a high-risk neoplasia for a patient.  
  
 For example, a 70 year-old woman who has never smoked or drunk, 
often practices sports, takes low-dose Aspirin and eats 4 meals of /fruits 
vegetables every day, had a total of 45 points, corresponding to a predicted 
probability of high-risk neoplasia of 15%. This woman resulted FOBT 
positive probably because of some acute and not serious intestinal issue, such 
as hemorrhoids. On the contrary, a 50-year man who drinks and smokes, eats 
a few vegetables and never practices sports obtains a large total of “risk 
points” and should have probably begun his screening program earlier than 50 
years old (Figure 3.5). 
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4. Risk factors at the second colonoscopy 
 
 
 
 After we demonstrated that lifestyle factors, gender, family history and 
low-dose Aspirin have an impact on the probability of finding a high-risk 
neoplasia at the first screening colonoscopy, we wanted to evaluate whether 
these factors have an impact on the probability of finding a high-risk neoplasia 
at the second screening colonoscopy. We used the linear predictor calculated 
in Chapter 3.4 in order to evaluate the association of the endoscopic finding 
with an individual risk score, rather than with all the single variables. 
  
 If a statistically significant association between the individual risk score 
and the outcome of the second screening colonoscopy is demonstrated, 
additional important conclusions will be drawn. The risk score should in fact 
possibly be considered when deciding how much time should pass from the 
first screening colonoscopy to the second control colonoscopy, basing future 
indications on the outcome of the primary colonoscopy as well as on the 
patients’ characteristics.  
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4.1 Doctor’s care scheme 
 
 
Only patients  diagnosed with adenoma at the first colonoscopy were 
included in the following analyses, because individuals with no adenoma and 
patients with invasive neoplasia were automatically excluded from the 
following colonoscopy screening process. The first group of individuals 
should have repeated FBOT after 5 years and the second group underwent a 
radical surgery and eventually an adjuvant therapy followed by a tight follow-
up.   
 
We focused on the follow-up of the patients and especially on the effect 
of lifestyle and other patients’ characteristics on all the possible neoplastic 
events between the first screening colonoscopy and the second control 
colonoscopy. Since many of the included patients were followed in time by 
IEO clinicians, according to a precise schedule based on the severity of 
clinical findings, we have the opportunity to study the evolution of the 
patients’ conditions. There is no general consensus on the timing of follow-up 
colonoscopies. This is what IEO clinicians recommend to screened patients, in 
accordance to the findings at colonoscopy. 
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 Normal mucosae or non-oncological alteration or non-adenomatous 
polyp: repeat FOBT at 5 years 
 1 or 2 adenomas: repeat colonoscopy at 5 years 
 3 or 4 adenomas: repeat colonoscopy at 3 years 
 5 or more adenomas: repeat colonoscopy at 1 year 
 Invasive tumour: in general, surgery plus visits every 6 months after 
treatment 
 
 
Table 4.1. Years from the 1st to the 2nd colonoscopy by severity of the 1st 
colonoscopy finding in 484 patients diagnosed with adenoma 
 
 
  Years form the first to the second colonoscopy  
  1 year 3 years 5 years Total 
Fi
rs
t 
co
lo
n
o
sc
o
py
 
 
1-2 low-risk adenomas 1 (2.6) 7 (18.4) 30 (78.9) 38 
1-2 high-risk adenomas 10 (9.2) 97 (89.0) 2 (1.8) 109 
3-4 adenomas 30 (30.3) 65 (65.7) 4 (4.0) 99 
> 4 adenomas 75 (88.2) 10 (11.8) 0 (0.0) 85 
 
Row percentages are reported in parentheses 
 
 
 
 
  
 Unfortunately, 153 patients did not come back for a second 
colonoscopy, making the number of patients analyzed in this phase 331. The 
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one depicted in Table 4.1 is a typical example of Doctor’s care scheme of 
examinations24. The second colonoscopy date was fixed in advanced at the 
time of first colonoscopy, based on the outcome of the first colonoscopy. 
Thirty patients out of 38 (78.9%) with 1 or 2 low-risk adenomas came back 
after 5 years; 97 out of 109 (89.0%) with 1 or 2 high-risk adenomas came 
back after 3 years; 75 out of 85 (88.2%) with 4 or more adenomas came back 
after 1 year.  
  
 The Doctor’s care scheme is highly relevant for many clinical studies 
because it allows the doctor monitoring the patient's progress to choose the 
next examination time for that patient depending on the state the patient is in 
at the current examination. In particular, patients with more advanced disease 
could be monitored more closely than those in whom disease was less 
advanced24. With regards to this, what we observed in our data is reported in 
Table 4.2. 
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Table 4.2. Outcome of the 2nd colonoscopy by severity of the 1st colonoscopy 
finding in 331 patients who had two colonoscopies 
 
 
 
  2nd colonoscopy 
  No adenoma Low-risk adenoma High-risk  
neoplasia Total 
1s
t  
co
lo
n
o
sc
o
py
 1-2 low-risk adenomas 28 (73.7) 6 (15.8) 4 (10.5) 38 
1-2 high-risk adenomas 53 (48.6) 40 (36.7) 16 (14.7) 109 
3-4 adenomas 45 (45.5) 34 (34.3) 20 (20.2) 99 
> 4 adenomas 17 (20.0) 34 (40.0) 34 (40.0) 85 
 
Row percentages are reported in parentheses 
 
 
 
 
Despite the Doctor’s care scheme, with differential visit times 
according to the severity of the first outcome, the outcome of the second 
colonoscopy was highly associated with the outcome of the first colonoscopy. 
The probability of finding a high-risk neoplasia at the second colonoscopy 
increased with the increasing severity of the outcome of the first. This was 
reasonable because a damaged mucosa remains damaged even after the 
removal all the polyps during a previous colonoscopy, hence a highly 
damaged mucosa tends to form new polyps more often than a less damaged 
mucosa.   
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 If we want to evaluate the effect of lifestyle on the outcome of 
the second colonoscopy, can we apply simple regression models by adjusting 
for the outcome of the first colonoscopy? In other words: is the doctor’s 
scheme a noninformative scheme? 
 
 In our case, information is incomplete in the sense that it is 
known only that an individual has been in certain disease states at several time 
points. Also, examination schemes are highly dependent on the outcome of 
the previous colonoscopy (see Table 5). The question is: can we apply a 
simple multivariable logistic model predicting the outcome of the second 
colonoscopy by using the finding of the primary colonoscopy plus the 
patients’ characteristics as covariates? Grüger et al.24, as I will show hereafter, 
demonstrated that it is possible to do so. 
 
 In order to interpolate models to longitudinal data with 
observation arbitrary visit times, one should consider the reason for which 
observations have been made in the time data. Possible schemes of 
observation are: 
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- Fixed: each patient is observed at fixed times, which are specified in 
advance; 
- Random: observation times vary randomly, regardless of the current state of 
the 
disease; 
- At the discretion of the physician or Doctor’s care: the observations for 
the sickest patients are more frequent. the next observation time is chosen on 
the basis of the current status of the disease; 
- Auto-selection of the patient: a patient decides to pay a visit to the doctor 
because he feels bad. 
 
Grüger and al. have discussed the conditions under which the 
observation times are informative. When considering a multi-state, ignoring 
the information contained in the observation time points could lead to a biased 
inference, because the times of observation should also be considered as 
random variable and modeled along with the observed process X(t). The ideal 
situation would be one in which the joint likelihood of time points and process 
is found to be proportional to the likelihood obtained in the case of time 
observation established a priori. In this way the parameters of the process can 
be estimated independently of the parameters of the sampling scheme. In 
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particular, the authors show that for the fixed, random and Doctor’s care 
schemes, observation times can be considered as non-informative, while, on 
the other hand, the self-selection of the patient leads to informative 
observation times. 
 
Suppose the disease process X(t) for a particular patient is observed at a 
finite number of fixed examination times t0 < t1 < … < tm to be in states s0, s1, 
..., sm. The likelihood is then given by 
 
   L0 = Pr( X(t0) = s0 ,…, X(tm) = sm) 
 
This is the likelihood that inferences are usually based on. However, in 
practical applications, examination times are seldom fixed in advance, but are 
subject to random fluctuations. In fact, not only are the examination times T0, 
T1 , . . . , Tm, random, but also their number M is a random variable. So one 
should instead consider the likelihood: 
 
L0 = Pr( X(t0) = s0 ,…, X(tm) = sm; T0 = t0,…, Tm= tm; M = m) 
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Our aim is to make inferences about the probability that a patient will 
be in a particular disease state at time t, regardless of whether an examination 
is performed at this and past times or not. So even if examination times are 
random, L0 is the likelihood we would like to analyze, because it contains the 
relevant transition probabilities. We therefore introduce the following 
definition. 
 
Definition An examination scheme (T0 = t0,…, Tm= tm; M = m) is called 
non-informative for the disease process X, if the full likelihood on the event { 
T0, . . , Tm; M = m } is proportional to the likelihood obtained, if the number 
of examinations and their times were fixed in advanced, i.e.,  
 
L =const *L0 
 
where the constant might depend on { T0, . . , Tm; M = m }, but not on X. 
A straightforward application of the definition of conditional 
probabilities yields a factorization of the full likelihood into 
 
L = Pr( X(t0) = s0 ,…, X(tm) = sm | T0 = t0,…, Tm= tm; M = m) x  
Pr(T0 = t0,…, Tm= tm; M = m)  
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Thus, any examination scheme that is stochastically independent of the 
process under observation is a noninformative examination scheme, because 
then the condition in the first factor of (3) can be ignored and the second 
factor is a constant with respect to the parameters of L0. 
Still this is not satisfactory, however, because often the independence 
assumption will be violated. […] In the "doctor's care" examination scheme 
the next examination time is chosen on the basis of the current observed 
disease state. For patients in the critical stage with an increased risk of dying, 
this time will be chosen in the very near future, whereas for patients in the 
stable stage, time intervals between successive examinations will be longer. 
We can cope with this situation by factoring the full likelihood in a 
dynamic fashion, which reflects the accumulation of information about the 
disease process in time. To this end we define the history H0 = {T0 = t0, X(t0) 
= s0 } and for j=1,…,m,  
 
Hj = {T0 = t0, X(t0), …, Tj = tj, X(tj) }; 
Hj- = {T0 = t0, X(t0), …, Tj = tj}. 
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Hj contains all the information about the disease process up to and 
including the jth examination, whereas Hj- includes only the time but not the 
result of the jth examination. Then by successively conditioning on the past 
we get  
 
L = Pr(Hm)= Pr(Hm | Hm-1) x Pr(Hm- | Hm-1) x Pr(Hm-1) 
= Pr(H0)  ∏ j | j-  x ∏ j- | j-1  
=Pr(H0) ∏  	
j    j |    
j, j-1  ∏  j   
j | j-1  
 
From this we can derive the following conditions for the examination 
scheme to be noninformative in the sense of the above definition: 
 
1. Pr( X(tj) = sj | Tj = tj, Hj-1 )= Pr( X(tj) = sj | X(t0) = s0,…, X(tj-1) = sj-1) 
2. The conditional distribution of the jth examination time Tj, i.e., Pr(Tj 
= tj | Hj-1) is functionally independent of parameters governing the 
transition intensities of X. 
 
The first of these two conditions is the important one, since it 
guarantees that what we can estimate from the data [i.e., Pr(X(tj) = sj I Tj = tj, 
Hj-1), the probability of being in state sj, given that examinations take place at 
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t0,…, tj] is identical to what we are interested in [i.e., Pr(X(tj) = sj I X(t0) = s0,. . 
. , X(tj-1) = sj-1 ), the probability of being in state sj, irrespective of whether an 
examination has taken place or not]. So past examinations should not exert 
any effect on the future behavior of the process. However, examination times 
may be based on all information available up to the last examination, i.e., the 
times of examinations and the disease states observed (quotes from Grüger24). 
 
Therefore, having demonstrated that the Doctor’s care scheme is 
noninformative, as it is not dependent on the status of the patient, we can use a 
standard logistic regression to model the outcome of the second colonoscopy, 
adjusting for the outcome of the primary colonoscopy as well as for the 
patients’ characteristics. 
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Table 4.3. Multivariable logistic regression analysis modeling the outcome of 
second colonoscopy 
 
  
High-risk neoplasia 
  OR  (95% C.I.) 
Linear predictor One unit increase 1.54 (1.02-2.42) 
Outcome of first  
colonoscopy 
1-2 low-risk adenomas 
vs > 4 adenomas 0.22 (0.05-1.07) 
1-2 high-risk adenomas 
vs > 4 adenomas 0.27 (0.11-0.71) 
3-4 adenomas 
vs > 4 adenomas 0.43 (0.20-0.94) 
Time from 1st to  
2nd colonoscopy One year increase 0.85 (0.61-1.18) 
 
 
  
  
 As expected, the severity of the outcome of the first colonoscopy 
resulted statistically significantly associated with the outcome of the second 
colonoscopy: patients with 1-2 low-risk adenomas at first colonoscopy had a 
much more lower risk of high-risk neoplasia at second colonoscopy compared 
to patients with more than 4 adenomas (OR=0.22; Table 4.3). Moreover, 
patients with 1-2 high-risk adenomas or 3-4 adenomas at first colonoscopy 
still had a much more lower risk of high-risk neoplasia at second colonoscopy 
compared to patients with 4 or more adenomas (OR=0.27 and 0.43, 
respectively).  
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 After adjusting for the severity of the outcome of the first colonoscopy 
and for the time from first to second colonoscopy, we obtained a statistically 
significant OR associated with the linear predictor. For each unit of increase, 
the risk of finding a high-risk neoplasia at the second colonoscopy increased 
by 54%. The poorer the lifestyle, the higher the probability of finding a high-
risk neoplasia at the second round, irrespective of the outcome of the first 
round.  
  
 These findings represented the most important in this second phase of 
our analysis, because we provided again – as we did before in the “First 
colonoscopy” chapter – strong evidence supporting the role in CRC 
carcinogenesis of physical activity, diet, smoke and alcohol habits, and 
medication use. Therefore, all these factors should be considered when 
deciding how much time should pass from the first screening colonoscopy to 
the second control colonoscopy, basing the future indications on the outcome 
of the primary colonoscopy as well as on the patients’ characteristics. 
 
 In a sensitivity analysis, we used the best FP1 (logarithmic 
transformation of the linear predictor, Table 4.4) instead of the simple linear 
function of the linear predictor (Table  4.3) and we obtained: 
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Table 4.4. Multivariable logistic regression analysis modeling the outcome of 
second colonoscopy 
 
  
High-risk neoplasia 
  OR  (95% C.I.) 
Log(Linear predictor) One unit increase 1.98 (1.10-3.56) 
Outcome of first  
colonoscopy 
1-2 low-risk adenomas 
vs > 4 adenomas 0.21 (0.04-1.03) 
1-2 high-risk adenomas 
vs > 4 adenomas 0.27 (0.10-0.71) 
3-4 adenomas 
vs > 4 adenomas 0.43 (0.20-0.95) 
Time from 1st to  
2nd colonoscopy One year increase 0.87 (0.62-1.21) 
 
 
 
 After adjusting for the severity of the outcome of the first colonoscopy 
and for the time from first to second colonoscopy, we obtained a highly 
statistically significant OR associated with the log(linear predictor). For each 
unit of increase, the risk of finding a high-risk neoplasia at the second 
colonoscopy doubles. Again, the more your lifestyle is bad, the higher the 
probability of finding a high-risk neoplasia at the second round, irrespective of 
the outcome of the first round. 
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Figure 4.1. Probability of high-risk neoplasia at second screening 
colonoscopy according to quintiles of the linear predictor: observed versus 
expected 
 
 
 
 
 
• AIC using linear predictor as covariate: 349.9. Hosmer–Lemeshow test 
P-value=0.42 
• AIC using the logarithmic transformation of the linear predictor as 
covariate (Best FP1): 345.9. Hosmer–Lemeshow test P-value=0.92 
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Since Hosmer–Lemeshow test was not significant we could not reject the null 
hypothesis that observed and expected values are the same, so we concluded 
that both models fitted the data well. Nevertheless, by comparing the two 
AICs, we could conclude that the model using the logarithmic transformation 
was better than the one using the linear predictor as covariate. 
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4.2 Multistate Markov Model 
 
The previous reported statistical analysis relies on simple two-state 
models, where one single event (the high-risk neoplasia) is taken as the 
outcome of interest. On the other hand, more than one endpoint can be defined 
in our case, such as no adenoma, low-risk adenoma and high-risk neoplasia. If 
one wants to take into account the different types of outcome, separate 
analyses are usually carried out for each of the endpoints and particular 
subgroups (i.e. multinomial logistic regression and competing risk survival 
analysis). These analyses are not completely satisfactory, since they fail to 
highlight the relations between different types of outcomes.  
 
Recently, methods that simultaneously model the disease process over 
time have been developed, like the multi-state models25. In particular, in 
recent times, some interesting applications of Multistate Markov Models to 
screening programs have been developed26. In our study, such models allowed 
us to evaluate the effect of lifestyle and other factors (summarized in the 
linear predictor) on each transition, and make some final conclusions 1) on the 
age at which CRC screening should begin, either by lowering the age in 
people leading an unhealthy lifestyle or increasing the age in people leading a 
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healthy lifestyle and 2) deciding whether the second control colonoscopy 
should be anticipated or delayed according to patients’ characteristics. 
 
Despite such models may require specialized and quite complicated 
analytical tools, they give a better insight on the disease progression 
mechanisms and on the evaluation of the influence of prognostic factors on 
the transition rates from one state of the disease to another27-29.  
 
A multi-state model is defined as a model that describes a stochastic 
process{X(t), 
  }, where for stochastic process we intend a family of 
random variables X indexed by t in T. Usually the parameter t is the time and 
the set T the temporal space. The sample space S of X (t) refers to the state 
space, with elements of S states. In the context of stochastic processes, the 
space S can be either discrete, consisting of a finite or denumerable infinity of 
states that the random variable X can assume, or consisting of continuous and 
non-countable infinity of states. Similarly T can be discrete or continuous. A 
multi-state model defines stochastic processes with discrete and finite sample 
space S and T continuous space-time.  
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In our case we deal with a 3-state process: the first is the “No adenoma” 
state, the second is the “Low-risk adenoma” and the third one is the “High-
risk adenoma”. The time between the first and the second colonoscopy is kept 
continuous. 
 
The structure of the states specifies which transitions from state to state 
are possible, and it can be represented graphically. The complete statistical 
model is defined by the stages structure matrix and the rule that governs the 
process.  
 
 
Figure 4.2. Complete statistical model 
 
 
 
 
 
 
 
 
State 1
No adenoma
State 2
Low-risk 
adenoma
λ23
λ21 λ32
λ31
State 3
High-risk 
neoplasia
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 None of the patients started from State 1, as we selected only patients 
having at least one adenoma at baseline. For each patient, the disease stage at 
time t is a variable X(t) which assumes values in {1,2,3}, having 3 stages. 
Stages structure matrix specifies the stages and the possible transitions from 
stage to stage. 
 
 
Table 4.5. Outcome of the 2nd colonoscopy by severity of the 1st colonoscopy 
finding 
 
 
  2nd colonoscopy 
  
No 
adenoma 
Low-risk  
adenoma 
High-risk 
adenoma  Total 
1s
t  
co
lo
n
o
sc
o
py
 No adenoma - - -  
Low-risk  
adenoma 28 (73.7) 6 (15.8) 4 (10.5) 38 
High-risk 
adenoma  115 (39.2) 108 (36.9) 70 (23.9) 293 
 
Row percentages are reported in parentheses 
 
 
 
Definition and formulations of general multi-state models can be found 
in Hougaard28, Commenges29 and Andersen and Keiding30. As we have seen, 
a multi-state process is a stochastic process in continuous time X(t) which can 
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take a finite number of states in the set S = {1, 2, ..., K}. For a given n and t0 < 
t1 <... < tn, the set of observed values {X(t0), X(t1), ..., X(tn)} of X(t) at times 
{t0, t1, ..., tn} is called path or history of the process and is indicated by Ψt. The 
history of the process is continuous on the right, such that X(t+) = X(t). 
 
The law which governs the multi-state process can be given in terms of 
both matrix of transition probabilities P(s,t) with generic element: 
 
hj,   	
   | 
  , s‐ 
 
for h, j S, s, t T, s<t, or in terms of transition intensity matrix Λ(t), whose 
generic element is the derivative: 
 
hj , t‐  

hj,    
 
        
 
To guarantee that the sum of transition probability from one specific 
state to any other state (including the same starting state) is one, we constrain 
the row sum in the transition matrix Λ(t) to be equal to zero, i.e. that λhh(t)= - 
∑j≠h λhj  
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The intensity of transition λhj can be interpreted as the instantaneous 
rate of change from the state h to the state j at time t, and λh(t) = - λhh(t) as the 
rate of exit from the state h at time t. 
 
Table 4.6. Transition intensity matrix (∆t=1 year) 
 
 State 1 State 2 State 3 
State 1 0 0 0 
State 2 0.215 - 0.742 0.527 
State 3 0.254 1.043 - 1.297 
 
-2(log-likelihood):  677.67 
 
 
Multi-state models and Markov models are not equivalent, but both 
share the concept of state. In short, the Markovian assumption implies that the 
future evolution of a condition depends only on the current state: in other 
words, all the information on the previous history of the disease process is 
contained in the state at time t. 
 
Markovian assumption: hjt, t-  hj
 
 
This assumption defines a non-homogeneous Markov model, because the 
intensity of transition may vary over time. 
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In our analysis we will use homogeneous Markov Models. it is assumed that 
the intensity of transition is not time-dependent: 
 
hj, 
     |           |      
    hj   hj 
 
 
If it is assumed that the heterogeneity could partly be explained by a vector of 
explanatory variables Zi that characterizes the subject, one can write: 
 

 
  
 
,  
 
 
In this case, the subjects all share the function hj (·,·), and the population can 
be defined homogeneous conditionally on Zi, i = 1, ..., M. An assumption that 
greatly simplifies the process of estimating the parameters of the model is that 
the values of the intensities conditioned to zi are proportional to a basal 
intensity: 
 

,    
  
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For analytical convenience and for an immediate interpretation of results in 
terms of usual relationship between risks, the model is reparameterized 
introducing covariates as a factor proportional to the intensity of the basic 
transition , so that we obtain a log-linear model for the intensities of 
transition. The regression for the element (h, j) of the transition matrix Λ is 
thus indicated: 
 
 
    !"#
′ $ 
 
 
with %′  vector of regression coefficients associated with the vector of 
covariates z for transitions between states h and j. It can then redefine the 
matrix of intensity transition in terms of the parameters  and %, and indicate 
it as Λ(z). 
 
 One can test whether the covariate z affects the transition intensities by  
comparing the likelihoods of the restricted model and the unrestricted model, 
through the likelihood ratio test. With regards to the practical implementation, 
we used the msm package of functions for multi-state modelling using the R 
statistical software31.  
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Figure 4.3. Possible transitions with linear predictor as covariate 
 
 
 
 
 
PredLin= linear predictor as calculated in chapter 3.4 
 
 
 
 
 
 
 
Table 4.7. Log-linear effects of linear predictor on transitions 
 
 State 1 State 2 State 3 
State 1 - 0 0 
State 2 - 0.121 - 0.261 
State 3 - 0.380 - 0.545 - 
 
-2(log-likelihood):  662.63 
 
 
 
The one reported in Table 4.7 was a very interesting result. The estimated 
parameters for the effects of linear predictor on improvement transitions 
(State 2  State 1 or State 3  State 2 or State 3  State 1) were negative, 
State 1
No adenoma
State 2
Low-risk
adenoma
λ23exp(β23 PredLin)
State 3
High-risk
neoplasia
λ32exp(β32 PredLin)λ21exp(β21 PredLin)
λ31exp(β31 PredLin)
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which means that as the linear predictor increased, the probability of getting 
better decreased. The interpretation is that, in other words, the worse the 
lifestyle, the lower the probability for the intestinal mucosa to heal. 
 
On the other hand, the estimated parameter for the effect of linear predictor on 
aggravation transition (State 2  State 3) was positive, which means that as 
the linear predictor increased, the probability of getting worse increased. In 
other words, the worse the lifestyle, the higher the probability for the intestinal 
mucosa to worsen. 
 
Moreover, we tested whether the introduction of the lifestyle as covariate 
added significant information to the simple transition model. The difference 
between -2 (log-likelihood) of the null model and the -2 (log-likelihood) of the 
model with lifestyle was given by 677.67-662.63=15.04 which distributes as a 
Chi-square with 4 degrees of freedom. Since the table value of a Chi-square 
with 4 degrees and α=0.05 is 9.49, we rejected the null hypothesis of no 
impact of lifestyle on the transition model. 
 
 
We also estimated the effects of the linear predictor on transitions by 
restraining the effects of lifestyle on contiguous transitions to be the same.  
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Table 4.8. Log-linear effects of linear predictor on transitions with restraints 
 
 State 1 State 2 State 3 
State 1 - 0 0 
State 2 - 0.320 - 0.523 
State 3 -0.044 - 0.320 - 
 
-2(log-likelihood):  664.99 
 
 
Since we obtained similar results, we chose the simpler model without 
restraints (Table 13). 
 
 Looking at the results of this analysis, we can say that the combination 
of lifestyle factors plus gender, family history and low-dose Aspirin use was 
significantly and independently associated not only with the probability of 
finding a high-risk neoplasia at the second colonoscopy, but also with the 
transitions from different disease states.  
 
  
81 
 
5. Conclusions 
 
All these results allow us to draw two main important conclusions: 
 
1) Besides gender and family history, which are well-known features 
associated with screening-detected colorectal neoplasia, also lifestyle 
factors – such as physical activity, smoking habits, alcohol 
consumption and diet – are associated with the outcome of the first 
screening colonoscopy. Also, long-term low-dose Aspirin use was an 
additional significant factor in predicting the outcome. All these factors 
may soon change the clinical practice about the age at which CRC 
screening should begin, either by lowering the age in individuals with a 
poor lifestyle or increasing the age in individuals with a healthy 
lifestyle. 
 
2) Lifestyle factors, with gender, family history and use of low-dose 
Aspirin, should be taken in consideration when deciding how much 
time should pass from the first screening colonoscopy to the second 
control colonoscopy, basing future indications not only on the outcome 
of the primary colonoscopy but also on the patients’ characteristics. 
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 Therefore, our findings increased the evidence that lifestyle is 
substantially associated with the carcinogenesis of the colorectal cancer. 
Having said that, two types of interventions are now possible, the first 
referring to the primary prevention (i.e. modification of lifestyle), and the 
second referring to the secondary prevention (i.e. modification of screening 
policies). Firstly, avoidance of smoking and heavy alcohol use, high 
consumption of fruits and vegetables, the maintenance of a reasonable level of 
physical activity and the use of low-dose Aspirin can each have a beneficial 
impact on the risk of colorectal cancer (primary prevention). Secondly, 
lifestyle should be considered in the planning of population colorectal cancer 
screenings (secondary prevention), because the identification of different risk 
groups can lead to more tailored screening policies and, accordingly, to more 
efficient and cost-effective interventions. 
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